A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Study Overview

The purpose of this study is to determine if Eltrombopag is as effective of a treatment for patients with newly diagnosed Immune Thrombocytopenia (ITP) when compared to standard treatment.

Study Description

Participants will not be paid for their participation.

IRB Number: 1905858882 (PHO-BAYLOR-ICON3)
Research Study Identifier: TX10529
Principal Investigator: Kerry Hege, MD

Recruitment Status

Open

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Open

A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Study Overview

Study Description

Recruitment Status

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Study Overview

Study Description

Recruitment Status

Contact the research team to learn more about this study. Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required